EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieOpen Access · CC BY 4.0

Relative Dose Intensity of Trabectedin and Outcome of Advanced L‐Sarcomas

Stephen Poitureau, Marie-Cécile Le Deley, Mehdi Brahmi, Emmanuelle Bompas iD, Jean-Emmanuel Kurtz, Simon Nannini, Christophe Perrin, Loïc Lebellec, Thomas Ryckewaert, Redha Ould-Ammar, Clémence Leguillette, Jean-Yves Blay und 1 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.71131 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Stephen Poitureau und 12 weiteren Autor:innen. Beteiligte Einrichtung: Lille University, Medical School, Lille, France. Hauptthemen laut MEDLINE: Antineoplastic Agents, Alkylating, Leiomyosarcoma, Liposarcoma, Trabectedin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Trabectedin, which is approved for advanced soft tissue sarcoma management, has a complex mechanism of action, but can be classified as an alkylating agent. The need to maintain a high relative dose intensity (RDI) is not clearly established in this clinical setting.

Methods

We conducted a retrospective study in five expert centers to compare the progression‐free survival (PFS) and overall survival (OS) of patients with advanced L‐Sarcomas (liposarcomas or leiomyosarcoma) according to the RDI calculated over the first three cycles (RDI < 80% and RDI ≥ 80%). Comparisons of patients' characteristics were done using Chi‐2, Fisher exact, and Wilcoxon tests. Associations between PFS/OS and RDI were estimated and tested in Cox models.

Results

Out of 332 patients treated with trabectedin between 09/1999 and 12/2021, 244 have received at least 3 cycles before progression. Among these 244 patients, the median RDI during the first 3 cycles was 83% (range, 48%–106%), the mean RDI was 81% (±14%) and 106 patients had RDI < 80%. An RDI < 80% was more frequently observed in patients treated in a center with a high volume of activity (82/169, 49%, vs. 24/75, 32%, p = 0.02), in patients who had previously received pazopanib (12/18, 67%, vs. 94/225, 42%, p = 0.04), and in patients who experienced grade 3 neutropenia during the first cycle (56/77, 73% vs. 35/127, 28%, p < 0.001). PFS did not significantly differ according to RDI ( p = 0.08): HR (< 80%/≥ 80%) = 0.79 (95% CI, 0.61–1.03), median PFS = 8.4 months (7.0–9.3) when RDI < 80% vs. 5.9 months (4.4–6.8) when RDI ≥ 80%. We observed no significant difference in terms of OS ( p = 0.53): HR (< 80%/≥ 80%) = 0.92 (95% CI, 0.70–1.20), median OS = 18.2 months (15.6–23.4) when RDI < 80% vs. 15.8 months (13.2–19.7) when RDI ≥ 80%.

Conclusion

This retrospective study does not support a link between high trabectedin RDI and PFS or OS for advanced L‐sarcoma patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, AlkylatingLeiomyosarcomaLiposarcomaTrabectedinAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedYoung AdultProgression-Free SurvivalRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

dose reductionrelative dose intensitysoft tissue sarcomatoxicitytrabectedin

Substanzen

Antineoplastic Agents, AlkylatingTrabectedin

Autor:innen und Institutionen

  • Lille University, Medical School, Lille, France.
  • Department of Clinical Research and Innovation, Centre Oscar-Lambret, Lille, France.
  • Université Paris-Sud, UVSQ, CESP, INSERM, Université Paris-Saclay, Villejuif, France.
  • Department of Medical Oncology, Centre Léon Bérard, University Claude Bernard Lyon I, Lyon, France.
  • Department of Medical Oncology, Institut de Cancérologie de L'ouest, Nantes, France.
  • Department of Medical Oncology, Institut de Cancérologie de Strasbourg-Europe, Strasbourg, France.

ORCID-Profile: Emmanuelle Bompas

Zitieren

APA

Poitureau, S., Le Deley, M. C., Brahmi, M., Bompas, E., Kurtz, J. E., Nannini, S., Perrin, C., Lebellec, L., Ryckewaert, T., Ould-Ammar, R., Leguillette, C., Blay, J. Y., & Penel, N. (2025). Relative Dose Intensity of Trabectedin and Outcome of Advanced L‐Sarcomas. Cancer Medicine. https://doi.org/10.1002/cam4.71131

Vancouver

Poitureau S, Le Deley MC, Brahmi M, Bompas E, Kurtz JE, Nannini S, et al. Relative Dose Intensity of Trabectedin and Outcome of Advanced L‐Sarcomas. Cancer Medicine. 2025. doi:10.1002/cam4.71131

BibTeX
@article{Poitureau2025,
  author = {Poitureau, Stephen and Le Deley, Marie-Cécile and Brahmi, Mehdi and Bompas, Emmanuelle and Kurtz, Jean-Emmanuel and Nannini, Simon and Perrin, Christophe and Lebellec, Loïc and Ryckewaert, Thomas and Ould-Ammar, Redha and Leguillette, Clémence and Blay, Jean-Yves and Penel, Nicolas},
  title = {Relative Dose Intensity of Trabectedin and Outcome of Advanced L‐Sarcomas},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71131}
}
Kostenlos starten →